Cancer Communications

Article	Citations
	602
	416
Treatment of Metastatic Cancer by Conferring Immunogenicity to the Apoptotic Bodies of the Primary Tumor	375
Correction to “Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges”	335
Issue Information	334
Loss of CDKN1B induces an age‐related clonal hematopoietic disorder via Notch2 activity dysregulation	288
Issue Information	259
Issue Information	231
Defining and tracing subtypes of patient‐derived xenograft models in pancreatic ductal adenocarcinoma	187
Dysregulated Proline Metabolism Exacerbates Hepatocellular Carcinoma Metastasis via EPRS1-Mediated mRNA Translation	180
Nine‐fold variation of risk of advanced colorectal neoplasms according to smoking and polygenic risk score: Results from a cross‐sectional study in a large screening colonoscopy cohort	172
Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study	170
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update	162
Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives	159
Single‐cell transcriptomics and epigenomics point to CD58‐CD2 interaction in controlling primary melanoma growth and immunity	157
Combined local therapy and CAR‐GPC3 T‐cell therapy in advanced hepatocellular carcinoma: a proof‐of‐concept treatment strategy	148
Long‐term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study	143
Current status and perspectives of esophageal cancer: a comprehensive review	142
Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial	131
EXPRESSION OF CONCERN: Discovery of a Novel Viroid‐Like Circular RNA in Colorectal Cancer	122
Single‐cell transcriptomics provides insights into the origin and immune microenvironment of cervical precancerous lesions	122
Issue Information	114
A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer	105
Issue Information	101
	101

	87
Impact of pre‐existing cardiometabolic diseases on metastatic cancer stage at diagnosis: a prospective multinational cohort study	83
Nasopharyngeal carcinoma treatment paradigm after HK0501 – a potential way forward	77
Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with h	77
Development and validation of an artificial intelligence model for predicting post‐transplant hepatocellular cancer recurrence	76
Oral transforming growth factor‐beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti‐tumor immunity	74
N 6 ‐methyladenosine‐regulated exosome biogenesis orchestrates an immunosuppressive pre‐metastatic niche in gastric cancer peritoneal metastas	73
Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5‐year update of	73
Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II‐III gastric cancer	72
Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer	69
Partial hepatectomy versus interventional treatment in patients with hepatitis B virus‐related hepatocellular carcinoma and clinically significant portal hypertension: a randomized comparative clinica	69
Comparative single‐cell analysis of esophageal cancer subtypes reveals tumor microenvironment distinctions explaining varied immunotherapy responses	67
Impact of small molecule‐mediated inhibition of ammonia detoxification on lung malignancies and liver metabolism	66
Cover Image, Volume 45, Issue 6	65
Association of previously irradiated stable brain metastases with outcomes of atezolizumab‐treated non‐small cell lung cancer: A pooled analysis of individual patient data from three randomized trials	65
Targeting IL‐17A to manage immunotherapy‐induced toxicity in melanoma	63
FOXO1 or not FOXO1: that is the question	62
Issue Information	59
First-Line Tislelizumab Combined with Bevacizumab and CAPOX for Metastatic Gastroesophageal Adenocarcinoma with Low Programmed Death-Ligand 1 Expression	58
Antitumoral effects of cannabis in Notch1 ‐mutated T‐cell acute lymphoblastic leukemia	58
A strong internal promoter drives massive expression of YEATS‐domain devoid MLLT3 transcripts in HSC and most lethal AML	57
Acquired RD3 loss regulates immune surveillance in high‐risk and therapy defying progressive neuroblastoma	56
Ubiquitination in cancer: mechanisms and therapeutic opportunities	53
Incidence of and survival with bone and soft tissue sarcoma: A nation‐wide study over four decades	53
Harnessing chimeric antigen receptor macrophages against solid tumors	52
Comprehensive DSRCT multi‐omics analyses unveil CACNA2D2 as a diagnostic hallmark and super‐enhancer‐driven EWSR1::WT1 signature gene	52
Novel molecular mechanisms of immune evasion in hepatocellular carcinoma: NSUN2‐mediated increase of SOAT2 RNA methylation	50
First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial	49
Correction to “Circulating tumor cells share RNA modules with early embryo trophectoderm and with metastatic cancer”	49
Low household income and income volatility increase risk of lung cancer: A nationwide retrospective cohort study	48
Transcriptomic analyses of localized prostate cancers of East Asian and North American men reveal race‐specific luminal‐basal and microenvironmental differences	48
Issue Information	47
Enhanced selection of people for lung cancer screening using AHRR (cg05575921) or F2RL3 (cg03636183) methy	46
An HGF‐dependent positive feedback loop between bladder cancer cells and fibroblasts mediates lymphangiogenesis and lymphatic metastasis	44
Breast cancer: an up‐to‐date review and future perspectives	44
m 6 A‐modified EHD1 controls PD‐L1 endosomal trafficking to modulate immune evasion and immunotherapy responses in lung adenocarcinoma	44
Development of antibody‐drug conjugates in cancer: Overview and prospects	43
4‐1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4‐1BB agonists	42
Inhibition of mTOR attenuates the initiation and progression of BRCA1 ‐associated mammary tumors	41
Genomic information of children with malignant brain tumors for the prediction of length of hospitalization	41
Vebreltinib for Previously Treated Astrocytoma, IDH -Mutant, Grade 4, and Glioblastoma, IDH Wild-Type with	41
Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract	40
Neuroinflammation drives apathy in cancer cachexia	40
Breaking barriers: The cGAS‐STING pathway as a novel frontier in cancer immunotherapy	39
circCAPRIN1 interacts with STAT2 to promote tumor progression and lipid synthesis via upregulating ACC1 expression in colorectal cancer	39
Long‐term antibiotic use and risk of hepatocellular carcinoma later in life: a nationwide cohort study of 9.8 million participants	39
	38
N‐acetyltransferase 10 promotes colon cancer progression by inhibiting ferroptosis through N4‐acetylation and stabilization of ferroptosis suppressor protein 1 (FSP1) mRNA	38
Issue Information	38
Issue Information	37

Cover Image, Volume 44, Issue 4	37
Knowing nodal Rouviére: the power of human intelligence in toxicity reduction	37
Single‐cell and bulk transcriptomics identifies a tumor‐specific CD36 + cancer‐associated fibroblast subpopulation in colorectal cancer	37
Issue Information	36
Pancreatic cancer survival trends in the US from 2001 to 2014: a CONCORD‐3 study	36
Preoperative Chemoradiotherapy versus Chemotherapy for Locally Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma: A Phase III Randomized Controlled Trial from China	34
Effect of neutrophils on tumor immunity and immunotherapy resistance with underlying mechanisms	34
Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium	34
Galectin 3‐binding protein (LGALS3BP) depletion attenuates hepatic fibrosis by reducing transforming growth factor‐β1 (TGF‐β1) availability and inhibits hepatocarcinogenesis	33
NSUN2 Promotes Cancer Immune Evasion via its Moonlighting Function Acting on Metabolic Reprogramming	33
Enhancement of CAR‐T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins	33
Lipid metabolism reprograming by SREBP1‐PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy	32
Breaking barriers: Smart vaccine platforms for cancer immunomodulation	32
Combination of photodynamic therapy and stimulator of interferon genes (STING) agonist inhibits colorectal tumor growth and recurrence	32
Tumor microenvironment signaling and therapeutics in cancer progression	31
	30
The Ly6g high Neutrophil Subset Dictates Breast Cancer Lung Metastasis via CD8 + T Cell Death	30
TOPK Suppresses the CD8 + T Cell Antitumor Immunity via Modulation of IRF5 Expression	29
Ex vivo STAT3 phosphorylation in circulating immune cells: a novel biomarker for early cancer diagnosis and response to anti‐PD‐1 therapy	29
A single measurement of fecal hemoglobin concentration outperforms polygenic risk score in colorectal cancer risk assessment	28
Issue Information	27
Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Study	27
Advanced precision modeling reveals divergent responses of hepatocellular carcinoma to combinatorial immunotherapy	27
Cover Image, Volume 43, Issue 6	27
Enhancing sensitivity of triple‐negative breast cancer to DNA‐damaging therapy through chemical inhibition of the m6A methyltransferase METTL3	26
Single‐cell‐eQTL mapping in circulating immune cells reveals genetic regulation of response‐associated networks in lung cancer immunotherapy	25
Targeting ferroptosis resistance resensitizes metastatic HR + HER2 − breast cancer cells to palboc	25
Leptin‐mediated suppression of lipoprotein lipase cleavage enhances lipid uptake and facilitates lymph node metastasis in gastric cancer	24
The regulatory roles and clinical significance of glycolysis in tumor	24
Real‐world outcomes of niraparib treatment in patients with ovarian cancer: a multicenter non‐interventional study in China	23
Harnessing the Power of CAR-NK Cells for Solid Tumors: Challenges, Innovations, and Future Frontiers in Immunotherapy	23
HMGB3 promotes brain metastasis of lung adenocarcinoma by recruiting SSBP1 for nuclear translocation to remodel mitochondrial metabolism	23
Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with ALK- Positive Non-Small Cell Lung Cancer	23
	23
Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors	23
In vivo intratumoral heterogeneity in a dish: scalable forebrain organoid models of embryonal brain tumors for high‐throughput personalized drug discovery	22
Lysosomal TMEM9‐LAMTOR4‐controlled mTOR signaling integrity is required for mammary tumorigenesis	22
Multiplexed CRISPR/Cas9 Editing of Tumor Suppressor Genes in the Mouse Endometrium Recapitulates High-Risk Endometrial Carcinoma	22
Perivascular localized cells commit erythropoiesis in PDGF‐B‐expressing solid tumors	22
Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients	21
Concurrent chemoradiotherapyof different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: A randomized, multicenter, phase III clinica	21
Targeting N4‐acetylcytidine suppresses hepatocellular carcinoma progression by repressing eEF2‐mediated HMGB2 mRNA translation	21
Targeted STAT1 therapy for LZTR1‐driven peripheral nerve sheath tumor	20
Tumor‐derived insulin‐like growth factor‐binding protein‐1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors	20
Dlk1 is a novel adrenocortical stem/progenitor cell marker that predicts malignancy in adrenocortical carcinoma	20
Single‐cell atlas reveals a distinct immune profile fostered by T cell‐B cell crosstalk in triple negative breast cancer	20
Transient and DNA‐free in vivo CRISPR/Cas9 genome editing for flexible modeling of endometrial carcinogenesis	20
The SARS‐CoV‐2 spike protein induces lung cancer migration and invasion in a TLR2‐dependent manner	20
Smoking, smoking cessation, and survival after cancer diagnosis in 128,423 patients across cancer types	19
Efficacy, safety and biomarkers of SG001 for patients with previously treated recurrent or metastatic cervical cancer: an open‐label, multicenter, phase Ib trial	19
Macrophages drive ferroptosis resistance after radiotherapy	19
TGFBR1 *6A and Risk for Colorectal Cancer	18
Diagnostic value of genetic mutation analysis and mutation profiling of cell‐free DNA in intraocular fluid for vitreoretinal lymphoma	18
TIMELESS Promotes LUAD Growth via Suppressing Transferrin-Mediated Ferroptosis and Reprograms the Tumor Microenvironment against Anti-PD-1 Immunotherapy	18
Excess Weight May Account for More Than 10% of All Cancers: The Underestimated Impact of the Obesity Epidemic	18
NHE7 upregulation potentiates the uptake of small extracellular vesicles by enhancing maturation of macropinosomes in hepatocellular carcinoma	18
Unraveling the routes to distant metastases in colorectal cancer: Tumor deposits and lymph node metastases as the gateway	17
RNA m 1 A methyltransferase TRMT61A promotes colorectal tumorigenesis by enhancing ONECUT2 mRNA stabil	17
Discovery of a novel viroid‐like circular RNA in colorectal cancer	17
Methionine restriction sensitizes cancer cells to immunotherapy	16
Issue Information	16
Engineering heavy chain antibody‐drug conjugates against solid tumors for a one‐shot kill	16
Cover Image, Volume 43, Issue 12	16
Lung cancer risk score for ever and never smokers in China	16
Issue Information	16
A phase II study on Mefatinib as first‐line treatment of patients with advanced non‐small‐cell lung cancer harboring uncommon EGFR mutations	16
Combating cancer immunotherapy resistance: a nano‐medicine perspective	15
Blockage of EGFR/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma	15
Cellular senescence and metabolic reprogramming: Unraveling the intricate crosstalk in the immunosuppressive tumor microenvironment	15
Exciting progress in targeted therapy innovation for unresectable stage III EGFR ‐mutated NSCLC: the phase III LAURA study	15
Combining methylated SEPTIN9 and RNF180 plasma markers for diagnosis and early detection of gastric cancer	15
	14
The Roles of Protein S -Palmitoylation in Cancers: From Dynamic Modulation to Therapeutic Potential	14
	14
Vascular smooth muscle cell plasticity in the tumor microenvironment	14
Dynamic epi‐transcriptomic landscape mapping with disease progression in estrogen receptor‐positive breast cancer	14
Transcription factor ETV4 promotes the development of hepatocellular carcinoma by driving hepatic TNF‐α signaling	14
MFSD2A potentiates gastric cancer response to anti‐PD‐1 immunotherapy by reprogramming the tumor microenvironment to activate T cell response	13
Nicotinamide N‐methyltransferase negatively regulates metastasis‐promoting property of cancer‐associated fibroblasts in lung adenocarcinoma	13
Issue Information	13

Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2‐positive gastric cancer	13
Lymphatic metastasis in non‐small cell lung cancer: recent discoveries and novel therapeutic targets	13
Stereotactic body radiotherapy plus cadonilimab (PD‐1/CTLA‐4 bispecific antibody) as third‐line or beyond therapy for refractory solid tumors: A phase 1b study	13
Decoding the Malignant Potential of Hydatidiform Moles through Fibroblast and LAIR2 Signatures	13
Cover Image, Volume 43, Issue 9	13
Plasma small‐extracellular vesicles enriched in miR‐122‐5p promote disease aggressiveness in pediatric anaplastic large‐cell lymphoma	12
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023	12
Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)‐T therapy has potential to reduce escape from single‐target CAR‐T with no more hematotoxicity	12
CD24 is a promising immunotherapeutic target for enhancing efficacy of third‐generation EGFR‐TKIs on EGFR‐mutated lung cancer	12
Effectiveness of Lung Cancer Screening by Sex and Tumor Histology: Extended, Pooled Analysis of the ITALUNG and LUSI Trials, with Comparison to Findings in the NLST	11
Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple‐negative breast cancer to immune checkpoint inhibitors	11
Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non‐small‐cell lung cancer characterizes the features of response to PD‐1 blockade plus chemotherapy	11
WTAP-Mediated Glutaminase Splicing Bias Suppresses Ferroptosis in Hepatocellular Carcinoma	11
Training the synergy between Bacillus Calmette‐Guérin and immune checkpoint‐blocking antibodies in bladder cancer	11
Intratumoral CD103 + CD8 + T cells predict response to neoadjuvant chemoimmunotherapy in advanced	11
Issue Information	11
Identification of telomere maintenance gene variations related to lung adenocarcinoma risk by genome‐wide association and whole genome sequencing analyses	10
Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial	10
Unveiling quality of clinical trial in China: from concern to confirmation	10
Semaglutide impairs bioavailability of alectinib: a note of warning based on a cross‐over pharmacokinetic drug‐drug interaction study	10
Targeting MAN1B1 potently enhances bladder cancer antitumor immunity via deglycosylation of CD47	10
Serologic status and safety of inactivated Covid‐19 vaccine for hepatocellular carcinoma patients with cirrhosis after curative liver resection	9
Endopharyngeal Ultrasound-Guided Transpharyngeal Needle Aspiration for Confirming Retropharyngeal Lymph Nodes’ Metastasis among Nasopharyngeal Carcinoma Patients	9
Issue Information	9
Cancer‐associated fibroblast‐derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib	9
	9
Issue Information	9
A serum exosomal microRNA‐based artificial intelligence diagnostic model for highly accurate detection of hepatocellular carcinoma	9
Cover Image, Volume 42, Issue 8	9
Simvastatin overcomes the pPCK1‐pLDHA‐SPRINGlac axis‐mediated ferroptosis and chemo‐immunotherapy resistance in AKT‐hyperactivated intrahepatic cholangiocarcinoma	9
Converting “cold” to “hot”: epigenetics strategies to improve immune therapy effect by regulating tumor‐associated immune suppressive cells	9
Dietary intake of advanced glycation endproducts (AGEs) and cancer risk across more than 20 anatomical sites: A multinational cohort study	9
NAT10 regulates tumor progression and immune microenvironment in pancreatic ductal adenocarcinoma via the N4‐acetylated LAMB3‐mediated FAK/ERK pathway	9
Cover Image, Volume 43, Issue 11	9
Tumor derived cell‐free nucleic acid upregulates programmed death‐ligand 1 expression in neutrophil via intracellular Toll‐like receptor signaling	9
	8
A practical overview and statistical analysis of interval‐censored data in cancer	8
Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors	8
Fusobacterium is toxic for head and neck squamous cell carcinoma and its presence may determine a better prognosis	8
Enhancing antitumor immunity through the combination of cholesterolized TLR7 agonist liposomes and radiotherapy: a role for IL‐1β and the inflammasome pathway	8
Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences	8
Neutrophils in cancer: At the crucial crossroads of anti‐tumor and pro‐tumor	8
The interplay between natural killer cells and pancreatic stellate cells in pancreatic ductal adenocarcinoma	8
A non‐metabolic function of hexokinase 2 in small cell lung cancer: promotes cancer cell stemness by increasing USP11‐mediated CD133 stability	8
Issue Information	8
Parkin deficiency promotes colorectal tumorigenesis and progression through RIPK3‐dependent necroptotic inflammation	8
Helicobacter pylori CagA elevates FTO to induce gastric cancer progression via a “hit‐and‐run” paradigm	8
miR‐99a‐5p modulates doxorubicin resistance via the COX‐2/ABCG2 axis in triple‐negative breast cancer: from the discovery to in vivo studies	8
Issue Information	8
Cytosolic TGM2 promotes malignant progression in gastric cancer by suppressing the TRIM21‐mediated ubiquitination/degradation of STAT1 in a GTP binding‐dependent modality	7
NAT10‐mediated ac 4 C‐modified ANKZF1 promotes tumor progression and lymphangiogenesis in clear‐cell renal cell carcinoma by attenuating YWHAE‐driven	7
Single‐cell transcriptomic analysis uncovers intratumoral heterogeneity and drug‐tolerant persister in ALK ‐rearranged lung adenocarcinoma	7
	7
Evaluation of exposure‐response‐safety relationship of model‐informed low‐dose 500 mg abiraterone acetate in prostate cancer patients	7
Non‐small cell lung cancer in China	7
Dysfunction of dendritic cells in tumor microenvironment and immunotherapy	7
Dual inhibition of sirtuins 1 and 2: reprogramming metabolic energy dynamics in chronic myeloid leukemia as an immunogenic anticancer strategy	7
Single‐cell multi‐omics reveals tumor microenvironment factors underlying poor immunotherapy responses in ALK‐positive lung cancer	6
Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies	6
Targeted reactivation of the novel tumor suppressor DAPK1, an upstream regulator of p53, in high‐grade serous ovarian cancer by mRNA liposomes reduces viability and enhances drug sensitivity in precli	6
“Find Me” and “Eat Me” signals: tools to drive phagocytic processes for modulating antitumor immunity	6
Multi‐omic study to unmask genes involved in prostate cancer development in a multi‐case family	6
Weakened humoral immune responses of inactivated SARS‐CoV‐2 vaccines in patients with solid tumors	6
Issue Information	6
Activation mechanisms of clinically distinct B‐Raf V600E and V600K mutants	6
Exposure of benzo[a]pyrene induces HCC exosome‐circular RNA to activate lung fibroblasts and trigger organotropic metastasis	6
Issue Information	6
Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor	6
SALIRI‐based (raltitrexed plus irinotecan) therapy as a second‐line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non‐interventional, registry study	6
Beyond the Gut: The intratumoral microbiome's influence on tumorigenesis and treatment response	6
Cover Image, Volume 45, Issue 12	6
Unraveling the effects of screening colonoscopy on colorectal cancer early detection and prevention: the NordICC trial revisited	6
	5
Anbenitamab in combination with chemotherapy in patients with HER2‐positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a multicenter, phase II s	5
Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions	5
Immunosuppressive JAG2 + tumor‐associated neutrophils hamper PD‐1 blockade response in ovarian cancer by mediating the differentiation of effector re	5
Low‐dose metronomic chemotherapy improves tumor control in nasopharyngeal carcinoma	5
Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors	5
	5
A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic	5
Copper in cancer: friend or foe? Metabolism, dysregulation, and therapeutic opportunities	5
Targeting SPHK1 in macrophages remodels the tumor microenvironment and enhances anti‐PD‐1 immunotherapy efficacy in colorectal cancer liver metastasis	5
Issue Information	5
	5
	5
Older adults living with gastrointestinal cancers in 2021	5
Aerobic glycolysis promotes tumor immune evasion and tumor cell stemness through the noncanonical function of hexokinase 2	5
Targeting RAS mutants in malignancies: successes, failures, and reasons for hope	5
Rescue of p53 functions by in vitro‐transcribed mRNA impedes the growth of high‐grade serous ovarian cancer	5
Integrated circulating tumor DNA and T cell repertoire predict radiotherapeutic response and outcome in non‐small cell lung cancer patients with brain metastasis	4
	4
Survival impact of early MRI progression after stereotactic radiotherapy for brain metastases	4
Sexual dimorphism in the antitumor immune responses elicited by the combination of fasting and chemotherapy	4
Tumor‐associated macrophages in liver cancer: From mechanisms to therapy	4
Tryptophan 2,3‐dioxygenase‐positive matrix fibroblasts fuel breast cancer lung metastasis via kynurenine‐mediated ferroptosis resistance of metastatic cells and T cell dysfunction	4